BACKGROUND: We used a Monte Carlo computer simulation to estimate the effectiveness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected men who have sex with men. METHODS: One-time screening for prevalent HCV infection was performed at the time of enrollment in care, followed by either symptom-based screening, screening with liver function tests (LFTs), HCV antibody (Ab) screening, or HCV RNA screening in various combinations and intervals. We considered both treatment with pegylated interferon and ribavirin (PEG/RBV) alone and with an HCV protease inhibitor. Outcome measures were life expectancy, quality-adjusted life expectancy, direct medical costs, and cost-effectiveness, assuming a societal willingness to pay $100000 per quality-adjusted life-year (QALY) gained. RESULTS: All strategies increased life expectancy (from 0.49 to 0.94 life-months), quality-adjusted life expectancy (from 0.47 to 1.00 quality-adjusted life-months), and costs (from $1900 to $7600), compared with symptom-based screening. The incremental cost-effectiveness ratio of screening with 6-month LFTs and a 12-month HCV Ab test, compared with symptom-based screening, was $43 700/QALY (for PEG/RBV alone) and $57 800/QALY (for PEG/RBV plus HCV protease inhibitor). The incremental cost-effectiveness ratio of screening with 3-month LFTs, compared with 6-month LFTs plus a 12-month HCV Ab test, was $129 700/QALY (for PEG/RBV alone) and $229 900/QALY (for PEG/RBV plus HCV protease inhibitor). With HCV protease inhibitor-based therapy, screening with 6-month LFTs and a 12-month HCV Ab test was the optimal strategy when the HCV infection incidence was ≤1.25 cases/100 person-years. The 3-month LFT strategy was optimal when the incidence was >1.25 cases/100 person-years. CONCLUSIONS: Screening for acute HCV infection in HIV-infected MSM prolongs life expectancy and is cost-effective. Depending on incidence, regular screening with LFTs, with or without an HCV Ab test, is the optimal strategy.
BACKGROUND: We used a Monte Carlo computer simulation to estimate the effectiveness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infectedmen who have sex with men. METHODS: One-time screening for prevalent HCV infection was performed at the time of enrollment in care, followed by either symptom-based screening, screening with liver function tests (LFTs), HCV antibody (Ab) screening, or HCV RNA screening in various combinations and intervals. We considered both treatment with pegylated interferon and ribavirin (PEG/RBV) alone and with an HCV protease inhibitor. Outcome measures were life expectancy, quality-adjusted life expectancy, direct medical costs, and cost-effectiveness, assuming a societal willingness to pay $100000 per quality-adjusted life-year (QALY) gained. RESULTS: All strategies increased life expectancy (from 0.49 to 0.94 life-months), quality-adjusted life expectancy (from 0.47 to 1.00 quality-adjusted life-months), and costs (from $1900 to $7600), compared with symptom-based screening. The incremental cost-effectiveness ratio of screening with 6-month LFTs and a 12-month HCV Ab test, compared with symptom-based screening, was $43 700/QALY (for PEG/RBV alone) and $57 800/QALY (for PEG/RBV plus HCV protease inhibitor). The incremental cost-effectiveness ratio of screening with 3-month LFTs, compared with 6-month LFTs plus a 12-month HCV Ab test, was $129 700/QALY (for PEG/RBV alone) and $229 900/QALY (for PEG/RBV plus HCV protease inhibitor). With HCV protease inhibitor-based therapy, screening with 6-month LFTs and a 12-month HCV Ab test was the optimal strategy when the HCV infection incidence was ≤1.25 cases/100 person-years. The 3-month LFT strategy was optimal when the incidence was >1.25 cases/100 person-years. CONCLUSIONS: Screening for acute HCV infection in HIV-infected MSM prolongs life expectancy and is cost-effective. Depending on incidence, regular screening with LFTs, with or without an HCV Ab test, is the optimal strategy.
Authors: Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce Journal: Value Health Date: 2003 Jan-Feb Impact factor: 5.725
Authors: K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Bruce R Schackman; Sue J Goldie; Kenneth A Freedberg; Elena Losina; John Brazier; Milton C Weinstein Journal: Med Decis Making Date: 2002 Jan-Feb Impact factor: 2.583
Authors: Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Christopher A K Y Chong; Anar Gulamhussein; E Jenny Heathcote; Les Lilly; Morris Sherman; Gary Naglie; Murray Krahn Journal: Am J Gastroenterol Date: 2003-03 Impact factor: 10.864
Authors: Martin Vogel; Emma Page; Christoph Boesecke; Thomas Reiberger; Carolynne Schwarze-Zander; Stefan Mauss; Axel Baumgarten; J-C Wasmuth; Mark Nelson; Jürgen K Rockstroh Journal: Clin Infect Dis Date: 2011-12-07 Impact factor: 9.079
Authors: Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman Journal: Ann Intern Med Date: 2013-01-15 Impact factor: 25.391
Authors: Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471
Authors: Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: Lynn E Taylor; Julie A Foont; Allison K DeLong; Alysse Wurcel; Benjamin P Linas; Stacey Chapman; Michaela A Maynard; Susan Cu-Uvin; Kenneth H Mayer Journal: AIDS Patient Care STDS Date: 2014-01 Impact factor: 5.078
Authors: Ali Jalali; Danielle A Ryan; Kathryn E McCollister; Lisa A Marsch; Bruce R Schackman; Sean M Murphy Journal: J Subst Abuse Treat Date: 2020-03